The San Francisco-based company is currently developing antibacterial non-antibody proteins against food and animal bacterial pathogens that the company calls Purocin proteins. AvidBiotics president and co-founder Jim Knighton told FierceAnimalHealth that these engineered proteins are "the antithesis of a broad spectrum antibiotic."
A new contraceptive implant developed by Lexington, MA-based MicroCHIPS could give women remote-controlled access to their hormone administration, offering up to 16 years of specifically dosed delivery and thus more authority over their birth control regimens.
AstraZeneca is expanding iMed, its virtual R&D project, through a cardiovascular-focused agreement with Germany's Max Planck Institute of Molecular Physiology that will focus on early-stage research.
Conventional imaging methods don't work so well in the gut, the site of irritable bowel syndrome, celiac disease and Crohn's disease among others. Researchers at the University of Buffalo say they have solved the problem, albeit in animal studies.
A novel intravaginal ring to prevent HIV showed promise in pig-tailed macaque monkeys, demonstrating the benefits of sustained and controlled topical drug delivery over oral intake.
Jan van de Winkel The Danish biotech Genmab has won a $25 million milestone from its $1.1 billion collaboration deal with Johnson & Johnson ($JNJ) on the CD38 antibody daratumumab. The...
Idexx in April reported a significant boost in Q1 revenues, as it heads toward its 2014 goal of nearly $1.5 billion in sales. With that growth has come hiring and to help accommodate the 240 people it has added in the last two years.
Bayer HealthCare has scored approval for the first chewable drug approved by the agency for treating osteoarthritis in dogs, a disease that accounts for pain in about 20% of canines older than one year.
When Y Combinator expanded into biotech, the startup incubator was effectively betting on the idea that IT has narrowed the gap between timelines and economics in life sciences and tech. The Wall Street Journal is the latest publication to profile the scene, picking out a batch of companies with similar models and ambitions to those featured by TechCrunch and FierceBiotechIT earlier this year.
The staff opposition that greeted news that the Scripps Research Institute is looking into a merger or other type of deal to ease its money worries has escalated over the past few weeks, culminating in an email to the chair of the board of trustees. In the email, Scripps' faculty leaders reportedly call for the removal of President Michael Marletta because they have lost confidence in his leadership.